PTC Therapeutics Provides Update On CHMP Opinion For Conditional Approval Of Ataluren For Nonsense Mutation Duchenne Muscular Dystrophy

Disease: 
Link: 
GUID: 
1 390 579 403
Time Stamp: 
1 390 579 403
Thumbnail: 
http://ir.ptcbio.com/common/alerts/PTCT/default/logo.gif
Node Type: 
Quest News